Cargando…

Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors

Detalles Bibliográficos
Autores principales:	Perez, Lia Elena, Fernandez, Hugo, Ayala, Ernesto, Beato, Francisca, Neuger, Anthony, Pidala, Joseph, Schell, Michael J., Anasetti, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382111/ https://www.ncbi.nlm.nih.gov/pubmed/27991896 http://dx.doi.org/10.1038/bmt.2016.330

Ejemplares similares

Tolerance Associated Gene Expression following Allogeneic Hematopoietic Cell Transplantation
por: Pidala, Joseph, et al.
Publicado: (2015)

Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2022)

The Presence of Anti-HLA Antibodies before and after Allogeneic Hematopoietic Stem Cells Transplantation from HLA-Mismatched Unrelated Donors
por: Koclega, Anna, et al.
Publicado: (2012)

Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2021)

The Effect of the COVID-19 Pandemic on Unrelated Allogeneic Hematopoietic Donor Collections and Safety
por: Parmar, Gaganvir, et al.
Publicado: (2023)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation
por: Pidala, Joseph, et al.
Publicado: (2018)

The Impact of HLA and KIR Ligand Mismatching on Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Korean Adult Patients
por: Park, Hyewon, et al.
Publicado: (2015)

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation
por: Betts, Brian C., et al.
Publicado: (2017)

Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation
por: Hahn, Theresa, et al.
Publicado: (2021)

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation
por: Dybko, Jarosław, et al.
Publicado: (2023)

Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis
por: Tie, Ruxiu, et al.
Publicado: (2017)

Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience
por: Mediwake, Heshani, et al.
Publicado: (2017)

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
por: Mayor, Neema P., et al.
Publicado: (2021)

Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR
por: Dehn, Jason, et al.
Publicado: (2019)

No Association between Donor Telomere Length and Outcomes after Allogeneic Unrelated Hematopoietic Cell Transplant in Patients with Acute Leukemia
por: Gadalla, Shahinaz M., et al.
Publicado: (2017)

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019)

HLA-C Incompatibilities in Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
por: Tiercy, Jean-Marie
Publicado: (2014)

Management of psychiatric complications in unrelated donor before unrelated peripheral hematopoietic stem cell collections
por: Hequet, Olivier, et al.
Publicado: (2016)

Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-versus-host disease
por: Pidala, Joseph, et al.
Publicado: (2022)

Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation
por: Inoue, Chiaki, et al.
Publicado: (2023)

Unrelated Hematopoietic Stem Cell Donor Matching Probability and Search Algorithm
por: Tiercy, J.-M.
Publicado: (2012)

2660. Infection Complications Following Mismatched Allogeneic Hematopoietic Cell Transplantation
por: Ebisu, Yosuke, et al.
Publicado: (2019)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

The kinetics of HTLV-1 proviral load after allogeneic hematopoietic cell transplantation with reduced intensity conditioning regimen; a comparison with that from sibling donors and that from unrelated donors
por: Choi, Ilseung, et al.
Publicado: (2014)

Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes
por: Jayani, Reena V., et al.
Publicado: (2021)

The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children
por: Park, Meerim, et al.
Publicado: (2011)

Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease
por: Schuetz, C., et al.
Publicado: (2008)

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
por: Ruggeri, Annalisa, et al.
Publicado: (2022)

The effectiveness of tacrolimus and minidose methotrexate in the prevention of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in children: a single-center study in Korea
por: Park, Seong Shik, et al.
Publicado: (2012)

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
por: Tang, Lu, et al.
Publicado: (2023)

Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients
por: Zhu, Jing, et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Unrelated Allogeneic Hematopoietic Peripheral Blood Progenitor Cell Collections in Canada
por: Seftel, Matthew, et al.
Publicado: (2023)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors
por: Berger, C, et al.
Publicado: (1999)

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
por: Butera, Sara, et al.
Publicado: (2021)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)

Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor
por: Lv, Weiran, et al.
Publicado: (2017)

Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders
por: Woolfrey, Ann, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_anqe354k1cvcesda8kkei0d2op